November 20, 2018 / 2:52 PM / 24 days ago

BRIEF-FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis

Nov 20 (Reuters) - Swedish Orphan Biovitrum AB (publ) :

* FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)

* SWEDISH ORPHAN BIOVITRUM - GAMIFANT IS EXPECTED TO BE AVAILABLE FOR ADMINISTRATION IN TREATMENT CENTERS ACROSS U.S. IN Q1 OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below